There is strong evidence for the involvement of α-synuclein in the pathologies of several neurodegenerative disorders, including PD (Parkinson's disease). Development of disease appears to be linked to processes that increase the rate at which α-synuclein forms aggregates. These processes include increased protein concentration (via either increased rate of synthesis or decreased rate of degradation), and altered forms of α-synuclein (such as truncations, missense mutations, or chemical modifications by oxidative reactions). Aggregated forms of the protein are toxic to cells and one therapeutic strategy would be to reduce the rate at which aggregation occurs. To this end we have designed several peptides that reduce α-synuclein aggregation. A cell-permeable version of one such peptide was able to inhibit the DNA damage induced by Fe(II) in neuronal cells transfected with α-synuclein (A53T), a familial PD-associated mutation.
Introduction
There are numerous findings suggesting a seminal role for α-synuclein in PD (Parkinson's disease) and several other neurodegenerative diseases. Firstly, α-synuclein is a component of Lewy bodies (inclusions present in brain regions that are functionally damaged in PD, dementia with Lewy bodies, and multiple system atrophy). Secondly, three missense α-synuclein mutations are linked to rare forms of early-onset familial PD [1] [2] [3] . Thirdly, α-synuclein forms toxic oligomers or fibrils. Also, raised α-synuclein expression in cells promotes mitochondrial deficit and cell death, enhances susceptibility to oxidative stress [4, 5] and can damage lysosomes [6] and the Golgi apparatus [7] . Finally, increased human α-synuclein expression in transgenic flies and mice is accompanied by neuronal dysfunction and loss of synaptic terminals and/or neurons, the formation of lesions similar to those found in PD brain, and the development of motor abnormalities [8, 9] . Taken together, all these studies provide strong evidence for a central role for α-synuclein deposition in the pathogenesis of these neurodegenerative disorders.
(phosphoneuroprotein 14) ] and γ -synuclein (also known as breast cancer-specific gene 1 or persyn), together with synoretin (in some references synoretin is grouped into the γ -synuclein subfamily) constitute a family of vertebrate-specific proteins [10] [11] [12] [13] [14] [15] [16] [17] .
The name 'synuclein' was first coined in 1988 by Maroteaux et al. [10] , when a protein (corresponding to the human γ -synuclein), present both in presynaptic nerve terminals and in the nuclear envelope of neurons, was isolated from the electric organ of Torpedo californica using an antiserum against cholinergic vesicles. Synucleins are cytosolic proteins of 123-143 residues with a high degree of primary structure homology; synucleins have 44% overall identity, β-synuclein shares 78% identity with α-synuclein and γ -synuclein shares 60% identity with α-synuclein [18] . The sequences of synucleins are characterized by a unique 11-residue repeat that occurs in five to seven copies and accounts for almost half of their structure.
α-and β-synucleins are detected in the brain, where they are predominantly expressed, constituting components of the presynaptic nerve terminals. In contrast, γ -synuclein is detected in a subset of neurons, but is also expressed in nonneuronal tissues [13, 17] , and is overexpressed in some breast cancer cells [15] .
α-Synuclein structure and function
α-Synuclein belongs to a family of closely related presynaptic proteins that are encoded by three distinct genes. In humans, minor spliced variants occur but the predominant form is a small, soluble protein of 140 residues that is abundantly expressed in neurons, where it is localized in presynaptic nerve terminals [18] .
The primary structure of α-synuclein is characterized by three distinct regions, namely the N-terminal region , the central region ) and the C-terminal region (96-140) ( Figure 1 ). The central region is composed of the extremely hydrophobic NAC (non-Aβ component of Alzheimer's disease amyloid) and the C-terminal region is rich in proline and the acidic residues glutamic and aspartic acid, and is hydrophilic. The most notable feature of the N-terminal and part of the central region of α-synuclein is the presence of seven repetitions of a degenerate 11-residue motif XKTKE-GVXXXA (where X is any amino acid), causing a repetitive variation in hydrophobicity [14] . The N-terminal and the hydrophobic NAC regions are highly conserved between species, while the C-terminal region is highly variable in size and in sequence [19, 20] and has been suggested to confer chaperone activity property to α-synuclein [21, 22] .
As far as the secondary structure of α-synuclein is concerned, the protein belongs to the family of natively unfolded proteins, which have little or no ordered structure under physiological conditions, and therefore α-synuclein has an extended structure composed of random coils [23] . Nevertheless, it should be noted that α-synuclein can bind to a number of proteins with a conformational transition to an α-helical conformation. The N-terminal region of the α-synuclein, and the 11-residue repeat motif in particular, are thought to be responsible for the α-synuclein assuming an α-helical conformation upon binding to lipid micelles [23, 24] and phospholipid membranes [25] . Furthermore, the NAC region of α-synuclein is highly amyloidogenic, and confers to the protein the ability to undergo a conformational change from random coil to β-sheet structure [26, 27] . In contrast, the acidic C-terminal region has been shown to remain unfolded and does not associate with vesicles or micelles [28] .
Although the function of α-synuclein is not clear, its association with synaptic vesicles indicates that it might play a role in the release of neurotransmitters [20, 29] . Developmental studies in songbirds suggest that its expression in certain neurons is associated with the acquisition of learning [14] and it is thought to play a role in synaptic plasticity, perhaps by helping to maintain the size of the presynaptic vesicular pool [30] . It has also been proposed that α-synuclein is an important regulatory component of vesicle transport in neuronal cells [31] . Furthermore, a number of studies have advocated a chaperone activity for α-synuclein because it appears, on one hand, to bind to many cellular proteins [32] [33] [34] [35] , and on the other hand, to share regions of homology with 14-3-3 proteins, which are a family of ubiquitous cytoplasmic chaperone proteins [4] . It should also be added that sequence resemblances of α-synuclein (residues 2-19 and 123-140) to fatty-acid-binding proteins have led to the suggestion that α-synuclein could be a novel brain-specific fatty-acid-binding protein [36] .
α-Synuclein aggregation
The findings that fibrillar α-synuclein is the major component of Lewy bodies [37] , and the A30P and A53T forms of α-synuclein, which are associated with autosomal dominantly inherited forms of PD, have higher rates of self-aggregation compared to wild-type α-synuclein [38, 39] , have led to the speculation that the aggregation of α-synuclein has a seminal role in PD. As a result, a lot of effort has been put into the elucidation of the mechanisms responsible for the polymerization and aggregation of α-synuclein. The modelling of kinetic and structural systems has shed light on many aspects of α-synuclein aggregation, but there are still many questions to be answered.
In vitro studies have shown that α-synuclein, the wildtype and the A53T and A30P mutated forms, are able to selfaggregate and form fibrils that structurally resemble those isolated from Lewy bodies and Lewy neurites [39] . The mutated forms, especially the A53T mutated form [39, 40] , of α-synuclein were shown to have higher aggregation rates, possibly because these mutations disrupt the α-helical structure of the protein in the N-terminal region. In fact, electron microscopy and circular dichroism studies of in vitro aggregated α-synuclein have demonstrated that the aggregation of the protein is accompanied by a conformational transition from random coil or α-helical structure to cross β-pleated sheet [26, 41] . Electron diffraction studies have revealed that the α-synuclein filaments have a β-sheet conformation that is similar to the structure described for other amyloid fibrils.
The fibrillation process of α-synuclein has been suggested to occur via protofilament formation, which in turn associate to produce filaments [39, 40] . Fibrils with diameters of 6-8 nm are referred to as protofibrils, while those with diameters of 10 nm and above are referred to as mature fibrils [27] . Fibrillation is a nucleation polymerization process, in which there is an initial lag phase, during which the nuclei are formed, followed by the exponential growth of the fibrils, and an equilibrium phase, which is characterized by the equilibrium between the protein in solution and the protein in fibrillar form [26, 38] . It has been shown that the fibrillation rate is dependent on: concentration, increasing with higher protein concentration [42] ; pH, increasing with a decrease in pH [43, 44] ; and temperature, increasing with increasing temperature [43] . α-Synuclein fibrillation rate can also be affected by the presence of heparin or other glycosaminoglycans [45] . [42, [46] [47] [48] , dopamine [49] , MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) [50, 51] , pesticides [51] and lipids [24, 52] . On the other hand, incubation of α-synuclein with β-synuclein and γ -synuclein inhibits in vitro α-synuclein aggregation [39] .
Scheme 1 illustrates a hypothetical scheme that depicts various proposed pathways of natively unfolded α-synuclein monomers converting into partially folded and/or aggregated forms.
α-Synuclein aggregation and toxicity
There are numerous findings suggesting that α-synuclein aggregation plays a seminal role in the pathogenesis of PD. Firstly, the main components of Lewy bodies are filaments of α-synuclein [37] , and in vitro studies have shown that recombinant α-synuclein can aggregate and form amyloid fibrils that resemble Lewy bodies [43, 53] . Secondly, three missense α-synuclein mutations are linked to rare forms of early-onset familial PD [1] [2] [3] , and they have been shown to increase α-synuclein oligomerization in vitro [39, 53, 54] . It has been shown that mutant α-synuclein contain more β-sheet structure than the wild-type protein [39, 40] . Thirdly, oxidative damage to α-synuclein makes the protein more prone to aggregation [46, 47, 55, 56] , as such damage might disrupt the ability of the N-terminus of α-synucleins to form α-helices, increasing the possibility of other more pathogenic conformations.
El-Agnaf et al. [41] reported that fresh and aged NAC (1-18) and NAC added directly to cultures of SH-SY5Y cells were toxic, with the aged NAC being more toxic than the fresh, suggesting that cytotoxicity depends on prior aggregation. During the early stages of PD, the amounts of the antioxidant GSH have been reported to reduce [57] , and it has been suggested that this decrease may be owing to an increase in the activity of the enzyme GGT (γ -glutamyltranspeptidase) and the conversion of GSH to its oxidized form, GSSG [58] . GGT promotes the removal of GSH from the cells and also catalyses its conversion into GSSG, which has been reported to facilitate amyloid formation by α-synuclein [59] . α-Synuclein has also been shown to aggregate in the presence of other oxidative stress-inducing compounds, including dopamine, MPTP, H 2 O 2 and the metals Fe 2+ and Cu 2+ [46, 48, 55, 56, 60] , and to generate H 2 O 2 [61] , initiating a vicious circle of oxidative stress and α-synuclein aggregation.
Experiments with GT1-7 hypothalamic cells revealed that overexpression of α-synuclein in these cells could generate α-synuclein-immunopositive inclusion-like structures, together with changes in mitochondria, increasing the production of free radicals [5] . As these alterations were minimized by antioxidants, such as vitamin E, it was suggested that the accumulation of α-synuclein could induce mitochondrial changes, which in turn could lead to oxidative stress and cell death [5] . Overexpression of α-synuclein has also been associated with lysosomal dysfunction [6, 62] and Golgi fragmentation [7] .
In an attempt to elucidate the role of truncated α-synuclein in PD pathogenesis, Liu et al. [63] studied the expression of full-length α-synuclein together with C-terminally truncated α-synuclein in human dopaminergic SH-SY5Y cells and reported that the C-terminally truncated α-synuclein increased α-synuclein-induced cell toxicity. Additionally, the co-expression of C-terminally truncated α-synuclein and full-length α-synuclein induced the formation of cytoplasmic inclusions and increased the susceptibility of the cells to oxidative stress. C-terminally truncated A53T α-synuclein was shown to induce the aggregation of fulllength A53T protein faster than its wild-type counterpart, suggesting that the mutation increases the accelerating effect that the truncated protein has on the aggregation of fulllength α-synuclein.
Inhibition of α-synuclein oligomerization as a therapeutic strategy
The conversion of some amyloidogenic proteins from random structure to β-sheet-rich aggregated structures can be blocked by the addition of a short synthetic peptide derived from the respective amyloidogenic protein (reviewed in [64] ). Such peptide inhibitors can also block the toxicity of amyloidogenic proteins both in vitro in cell-culture models and in vivo in animal models, suggesting that these peptide inhibitors could be useful therapeutically. We have designed such short synthetic peptides and tested their ability to inhibit the aggregation of NAC and α-synuclein into toxic oligomers. Our previous work indicated that the minimum fragment that formed fibrils and exhibited toxicity towards cells in culture was α-synuclein (68-78) [65] . We then adopted the approach, successfully used by Hughes et al. [66] for the Alzheimer peptide Aβ (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) , of inserting an N-methylated amino acid to provide a β-sheet-breaking peptide, since the methyl group is unable to form hydrogen bonds and so disrupts β-strand associations; hence we made an N-methylated derivative of α-synuclein (68-78) by replacing Gly 73 with sarcosine. This peptide, in equimolar mixture with the nonmethylated peptide, prevented fibril formation and reduced toxicity markedly [67] .
An alternative strategy that we have employed to design aggregation blockers was to identify synuclein fragments that bind to full-length α-synuclein. To this end, an overlapping library of biotin-tagged 7-mer peptides covering the whole α-synuclein sequence was constructed and each member was incubated with α-synuclein immobilized on a microtitre plate. Binding was revealed by probing with an avidinalkaline phosphatase conjugate [68] . This study revealed that peptides derived from the N-terminal half of the NAC region bound best to the full-length α-synuclein. Since this region is very hydrophobic, peptides derived from it are insoluble in aqueous solution, and to overcome this we placed a hydrophilic residue (arginine) at the N-and the C-terminus. Such modified short peptides from part of this binding region were found to interact with full-length α-synuclein and block its assembly into both early oligomers and mature amyloidlike fibrils. The peptide RGAVVTGR-amide was the shortest that retained the ability to inhibit synuclein aggregation. We also developed a cell-permeable inhibitor of aggregation, the peptide RGGAVVTGRRRRRR-amide, using the polyarginine-peptide delivery system. This peptide was able to inhibit the DNA damage induced by Fe(II) in neuronal cells transfected with α-synuclein (A53T), a familial PD-associated mutation. Related peptides without this delivery system did not reverse levels of Fe(II)-induced DNA damage.
The peptides described above are relatively small and so may provide the starting point for the design of metabolically stable peptidomimetic drugs for therapy in the synucleinopathies.
